What is Aktis Oncology, Inc.'s Shariah compliance score?

Aktis Oncology, Inc.'s (AKTS) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Aktis Oncology, Inc. pass AAOIFI screening?

Aktis Oncology, Inc. (AKTS) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (AKTS: 0.8%), (3) interest-bearing deposits below 30% (AKTS: 3.9%), and (4) prohibited income below 5% (AKTS: 219.1%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Aktis Oncology, Inc. stock?

Aktis Oncology, Inc. (AKTS) has a non-permissible income ratio of 219.14%. Muslim investors should purify this percentage of any dividends received and capital gains realized from AKTS shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Aktis Oncology, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Aktis Oncology, Inc. (AKTS) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about AKTS's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

AKTS: Is Aktis Oncology, Inc. Halal?

Aktis Oncology, Inc.

NASDAQHealthcareUS

$27.88

-1.90%

Market Cap: 1.5B

Compliance Status

Not Halal

Screened on Jul 20, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Aktis Oncology, Inc. (AKTS) halal? Not Halal. Based on AAOIFI screening, Aktis Oncology, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.8% of 30.0% limit

What this means for you

Most scholars advise not holding AKTS

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 20, 2026

Compliance History

Not Halalnow
since Jun 2026
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.45

-0.02%

0002.KLA+

Kotra Industries Bhd

$3.72

+0.01%

0075.KLA+

LYC Healthcare Bhd

$0.01

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.47

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.29

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track AKTS and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Aktis Oncology, Inc. (AKTS) halal to invest in?

Aktis Oncology, Inc. (AKTS) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Aktis Oncology, Inc. get a F compliance rating?

Aktis Oncology, Inc. (AKTS) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.8% (limit 30%); interest-bearing deposits of 3.9% (limit 30%); prohibited income of 219.14% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Aktis Oncology, Inc.'s Shariah verdict?

Aktis Oncology, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Aktis Oncology, Inc. re-screened for Shariah compliance?

Aktis Oncology, Inc. (AKTS) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 20, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.